当前位置: X-MOL 学术Breast Cancer Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Breast Cancer Research ( IF 6.1 ) Pub Date : 2020-01-22 , DOI: 10.1186/s13058-019-1240-y
Samuel A Jacobs 1 , André Robidoux 1, 2 , Jame Abraham 1, 3 , José Manuel Pérez-Garcia 4, 5 , Nicla La Verde 6, 7 , James M Orcutt 1, 8 , Marina E Cazzaniga 5, 9 , Fanny Piette 10 , Silvia Antolín 11 , Elena Aguirre 5 , Javier Cortes 4, 5 , Antonio Llombart-Cussac 5 , Serena Di Cosimo 5, 12 , Rim S Kim 1 , Huichen Feng 1 , Corey Lipchik 1 , Peter C Lucas 1, 13 , Ashok Srinivasan 1 , Ying Wang 1 , Nan Song 1 , Patrick G Gavin 1 , April D Balousek 1 , Soonmyung Paik 1, 14 , Carmen J Allegra 15 , Norman Wolmark 1, 16 , Katherine L Pogue-Geile 1
Affiliation  

After the publication of this work [1] the authors have reported that in Table 3 The letter "T" in columns 5 and 7 should not be there.

中文翻译:

校正至:NSABP FB-7:HER2 +乳腺癌的第二期随机新辅助试验,使用紫杉醇+曲妥珠单抗和/或neratinib联合化疗和曲妥珠单抗术后。

在发表这项工作[1]之后,作者报告说,在表3中,第5列和第7列中的字母“ T”不应存在。
更新日期:2020-04-22
down
wechat
bug